Harmony Biosciences (NASDAQ:HRMY) Rating Lowered to Hold at Wall Street Zen

Harmony Biosciences (NASDAQ:HRMY) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also issued reports on the stock. Mizuho set a $50.00 price target on shares of Harmony Biosciences in a report on Thursday, February 19th. UBS Group lowered their target price on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research note on Wednesday, February 25th. Oppenheimer restated an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a report on Monday, November 24th. Zacks Research downgraded Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $42.67.

Harmony Biosciences Stock Down 1.8%

Shares of NASDAQ:HRMY opened at $28.54 on Friday. The firm has a market cap of $1.65 billion, a P/E ratio of 10.53, a P/E/G ratio of 0.39 and a beta of 0.88. Harmony Biosciences has a 12-month low of $25.52 and a 12-month high of $40.87. The business has a fifty day simple moving average of $36.01 and a 200 day simple moving average of $34.05. The company has a quick ratio of 3.58, a current ratio of 3.60 and a debt-to-equity ratio of 0.17.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. The company had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. During the same quarter last year, the firm posted $0.85 EPS. The company’s quarterly revenue was up 21.1% on a year-over-year basis. Analysts predict that Harmony Biosciences will post 2.43 earnings per share for the current year.

Insider Activity

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sandip Kapadia sold 20,961 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,640 shares of company stock worth $1,932,256 in the last quarter. Company insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in shares of Harmony Biosciences by 4,102.4% in the 4th quarter. SG Americas Securities LLC now owns 961,667 shares of the company’s stock worth $35,986,000 after purchasing an additional 938,783 shares in the last quarter. Boston Partners acquired a new position in Harmony Biosciences during the second quarter worth $19,398,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Harmony Biosciences by 127.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock valued at $28,658,000 after buying an additional 508,498 shares in the last quarter. Armistice Capital LLC bought a new position in shares of Harmony Biosciences in the fourth quarter valued at $18,710,000. Finally, AQR Capital Management LLC grew its holdings in shares of Harmony Biosciences by 128.9% during the fourth quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after buying an additional 458,321 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Key Headlines Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.